IP Library Granted Patent US 8,946,412
Granted Patent B2
US 8,946,412 · App. 13/516,350 · Granted Feb 3, 2015

Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,946,412
App. No.
13/516,350
Granted
Feb 3, 2015
Kind
B2
Abstract

This invention relates to diazabicyclononyl oxadiazolyl derivatives, which are found to-be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances. Ar 1 represents a pyrrolyl group, optionally substituted with alkyl or halo-alkyl.

Claims (11)

1. A diazabicyclononyl oxadiazole derivative represented by Formula I

or a pharmaceutically acceptable salt thereof, in labelled or un-labelled form, wherein Ar 1 represents a pyrrolyl group substituted with labelled halo-alkyl.

2. The diazabicyclononyl oxadiazole derivative of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Ar 1 represents a pyrrolyl group substituted with 18 F-labelled fluoro-alkyl.

3. The diazabicyclononyl oxadiazole derivative of claim 1 , which is

2-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-5-[1-(2-fluoroethyl)pyrrol-2-yl]-1,3,4-oxadiazole; or

2-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-5-[1-(2-[ 18 F]fluoroethyl)pyrrol-2-yl]-1,3,4-oxadiazole;

or a pharmaceutically acceptable salt thereof.

4. The diazabicyclononyl oxadiazole derivative of claim 1 , which is

2-(1,4-Diazabicyclo[3.2.2]nonan-4-yl)-5-[1-(2-[ 18 F]fluoroethyl)pyrrol-2-yl]-1,3,4-oxadiazole;

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a therapeutically effective amount of a diazabicyclononyl oxadiazole derivative of any one of claims 1 - 4 , or a pharmaceutically acceptable salt thereof together with at least one pharmaceutically acceptable carrier or diluent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2013
From: NEUROSEARCH A/S
To: DANPET AB
Reel/Frame 029811/0215 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 12, 2012
From: PETERS, DAN; TIMMERMANN, DANIEL B.; NIELSEN, ELSEBET OSTERGAARD; DYHRING, TINO; AHRING, PHILIP K.
To: NEUROSEARCH A/S
Reel/Frame 028535/0020 →